1 Cross-ancestry analysis identifies genes associated with obesity risk

2 and protection

3			
4	Deepro Banerjee ^{1,2} and Santhosh Girirajan ^{1,2,3}		
5			
6	1. Bioinformatics and Genomics Graduate Program, The Huck Institute of the Life		
7	Sciences, University Park, PA 16802		
8	2. Department of Biochemistry and Molecular Biology, Pennsylvania State University,		
9	University Park, PA 16802		
10	3. Department of Anthropology, Pennsylvania State University, University Park, PA 16802		
11			
12			
13			
14			
15			
16			
17	Correspondence:		
18	Santhosh Girirajan		
19	205A Life Sciences Building		
20	Pennsylvania State University		
21	University Park, PA 16802		

22 E-mail: sxg47@psu.edu

23 ABSTRACT

- 24 Gene discoveries in obesity have largely been based on European cohorts, leading to an ancestral
- 25 bias, that limits their generalizability across populations. We performed a gene-based rare variant
- association study of 721,941 individuals and identified 116 novel BMI-associated genes with
- 27 consistent effects across ancestries, including 50 risk-conferring and 66 protective genes against
- 28 obesity. Protective genes such as *DCUN1D3* and *NEUROD6* had effect sizes comparable to
- 29 high-risk genes such as MC4R and BSN, and nearly twice that of known protective genes such as
- 30 *GPR75*, which, along with five other genes, showed strong European bias. Notably, 82 of the
- 31 116 genes showed functional relevance to obesity including adiposity, energy homeostasis, and
- 32 glucose metabolism. While polygenic risks or an obesogenic lifestyle amplified the effect of 15
- 33 genes on BMI, including the combination of low physical activity and *MACROD1*, 23 genes
- 34 including VIRMA, AQP3, and PML retained protective effects even at high polygenic scores. Our
- 35 findings provide further insights into the genetic basis of obesity that is conserved across

36 ancestries and their interactions with obesogenic factors.

37

39 MAIN

40 Obesity is a complex, heritable disorder with significant global impact, contributing to numerous 41 comorbidities and public health challenges¹. It is influenced by a combination of genetic and 42 lifestyle factors^{2,3}, yet the genetic component underlying the etiology of obesity remains a key 43 area of investigation. While large-scale studies have identified roles for common variants⁴, 44 including significant effects of polygenic risk scores (PGS)⁵, and rare protein-truncating variants in obesity risk genes such as MC4R and BSN^{6-9} , as well as protective genes such as $GPR75^9$, 45 46 these studies have predominantly focused on populations of European ancestry. Non-European 47 populations are often underrepresented or included only for replication purposes^{6–8}. This lack of 48 diversity in genetic studies has resulted in two major issues: a bias in gene discovery towards a 49 specific ancestry, and a limited ability to detect associations that may be significant in non-50 Europeans but lack statistical power in predominantly European cohorts¹⁰. For example, 51 clinically significant variants in APOL1 and PCSK9 associated with kidney disease and low LDL 52 cholesterol, respectively, were both discovered in populations of African ancestry^{11,12}. The 53 consequences of this bias extend beyond gene discovery, affecting the generalizability of 54 obesity-related findings to the broader global population and potentially limiting the 55 effectiveness of precision medicine approaches¹³. 56 Here, we conducted a rare variant association analysis of body-mass index (BMI) using 57 genetic and phenotypic data from 721,941 adults of diverse ancestries, leveraging cohorts from 58 the UK Biobank (UKB) and the All of Us (AoU) initiative. Unlike previous rare variant 59 association studies of BMI that prioritized European populations for discovery and non-60 Europeans for replication, we adopted a discovery approach in non-European populations as

61 well. Combining statistics across populations, we identified 121 genes, 116 of which have not

62 been previously linked to BMI in the context of rare variants, that showed consistent risk-

63 conferring and protective effects across ancestries. Our findings also revealed a strong European

bias in previously identified obesity genes, with effect sizes varying significantly in non-

65 European populations. These disparities highlight the critical need for more inclusive genomic

66 studies to ensure equitable obesity interventions.

67

68 **RESULTS**

69 Cross-ancestry analysis to identify BMI-associated genes

70 We analyzed genetic and electronic health record data of 721,941 adults from the UKB and AoU 71 cohorts representing six ancestries^{14,15}. We divided the cohorts into five populations, each with at least 50,000 individuals (Table 1). We used REGENIE v3.3¹⁶ to perform gene-burden 72 73 association tests by collapsing ultra-rare (minor allele frequency <0.1%) protein truncating 74 variants (PTVs, defined as predicted loss of function or deleterious missense variants) for each 75 gene and measuring their effect on BMI for each independent population. Using Bonferroni 76 multiple testing correction (P< 8.34×10^{-7} , 20,000 genes, and three variant collapsing models, see 77 **Methods**) and sample size (N \geq 20) thresholds, we identified a total of 11 BMI-associated genes 78 from the UKB British (MC4R, PCSK1, DIDO1, BSN, UBR2, ATP5PO, APBA1, SLC12A5, and 79 ATP13A1) and AoU European (MC4R, HECTD4 and YLPM1) populations, while no significant 80 genes were found in the UKB non-British, AoU African, or AoU mixed populations, potentially 81 due to insufficient statistical power to detect any association (Supplementary Table 1). 82 Therefore, to identify genetic associations that are consistent across populations, we performed 83 random-effect inverse variance weighted meta-analysis¹⁷ by aggregating summary statistics from 84 each population into European (UKB British and AoU European populations), non-European 85 (UKB non-British, AoU African, and AoU mixed populations), and combined (all five 86 populations) results. Gene-burden associations that passed multiple testing correction in either 87 the European or non-European meta-analysis, as well as in the combined result, were considered 88 to be significant gene-BMI associations across ancestries. In contrast to previous cross-ancestry 89 studies of BMI where European meta-analysis was typically used for discovery and non-90 European analysis for replication, we did not define a single discovery population. Instead, we 91 applied the same discovery approach in both populations, such that discoveries in Europeans 92 were replicated in non-Europeans, and vice versa. This strategy allowed us to detect association 93 signals for BMI in both populations, with consistent effect sizes. 94 Using our cross-ancestry approach, we discovered 116 novel genes (50 associated with

95 increased BMI and 66 with decreased BMI), along with five genes (*APBA1*, *BSN*, *MC4R*,

96 *ROBO1*, and *UBR2*) that were previously identified in rare-variant studies on BMI^{6,7,9,18} (Fig. 1,

97 Supplementary Tables 2, 3 and 4). We found that 28 out of the 33 known BMI-associated

98 genes did not pass the exome-wide significance threshold, including six genes (GPR75, PTPRG,

99 SPARC, RAB21, ATP13A1, and DIDO1) that were only significant in Europeans but not in the

- 100 combined meta-analysis (Supplementary Table 5). This result is consistent with a recent study
- 101 by Zhao and colleagues where the association of ATP13A1 with BMI did not replicate in a non-
- 102 European cohort⁷. In contrast, we found that *GIPR* showed a significant effect in non-Europeans
- 103 (β =-1.12 kg/m², 95% CI: -1.54, -0.70, *P*=1.67x10⁻⁷) but not in Europeans (β =-0.44 kg/m², 95%
- 104 CI: -0.89, 0.05, P=0.09). We did not find significance for some genes such as KSR2, ZFHX3,
- and *RAPGEF3*, where previous associations were driven by specific protein-altering variants⁶,
- 106 while for other genes such as ANO4, DPP9, and TOX4 cohort-specific biases may have driven
- 107 previous associations. For instance, Zhao and colleagues failed to replicate the association of
- 108 *TOX4* in a non-European cohort⁷ (Supplementary Fig. 1, Supplementary Table 5).
- 109
- 110 **Table 1**: Cohort and population statistics analyzed in this study.

Population	European	Non-European	Combined
UKB British	419,228		419,228
UKB non-British		68,070	68,070
(includes African, East Asian, South			
Asian ancestries)			
AoU European	127,644		127,644
AoU African		54,865	54,865
AoU Mixed		52,134	52,134
(includes Latino/admixed American,			
East Asian, South Asian and Middle			
Eastern ancestries)			
Meta population (N)	546,872	175,069	721,941

111

112 In our discovered genes, *MYOG* (β =3.87 kg/m², 95% CI: 3.14, 4.6, *P*=0), *ZFC3H1*

113 (β =1.78 kg/m², 95% CI: 1.53, 2.02, *P*=0), and *TMEM229A* (β =1.77 kg/m², 95% CI: 1.47, 2.07,

- 114 *P*=0) contributed to the highest increase in BMI, with effect sizes comparable to *MC4R*, *BSN*,
- and UBR2. In fact, we identified 40 such high-effect genes, including 24 BMI increasing and 16
- 116 BMI decreasing, which contributed to at least 1 kg/m² change in BMI (Fig. 1, Supplementary
- 117 **Table 4**). The effect sizes of several BMI-increasing genes, including *MACROD1*, *ICE1*, *ADNP*,
- 118 NACC2, and LPCAT4, were robust and showed minimal variability across ancestries

- (interpopulation variance, $V_{\beta} < 0.15$) (Fig. 2, Supplementary Table 6). Similarly, BMI-
- decreasing genes such as B3GNT2 (V_{β} =0.06), SNAP29 (V_{β} =0.10), VIRMA (V_{β} =0.13), and CCT7
- 121 $(V_{\beta}=0.13)$ showed more consistent effect sizes than previously reported protective genes,
- 122 including *GPR75* (V_{β} =1.06) and *GPR151* (V_{β} =0.49) (**Fig. 2, Supplementary Table 6**). Further,
- 123 the absolute effect sizes of BMI-decreasing genes, *DCUN1D3* (β =-3.84 kg/m², 95% CI: -4.6, -
- 124 3.09, P=0), NEUROD6 ($\beta=-3.02 \text{ kg/m}^2$, 95% CI: -4.16, -1.89, $P=1.8 \times 10^{-7}$), and SH3GL2 ($\beta=-$
- 125 2.34 kg/m², 95% CI: -3.05, -1.63, $P=1.16 \times 10^{-10}$) were comparable to those of *MC4R* and *BSN*.
- 126 These results highlight the robustness of our cross-ancestry gene discovery approach.
- 127





Fig. 1: Monogenic genes contributing to at least 1.5 kg/m² difference in BMI across

- 130 **ancestries**. Effect sizes along with 95% confidence intervals (CI) and significance values (*P*
- 131 value) in European, non-European, and combined meta-analysis for high-effect (>1.5 kg/m²)
- genes associated with (a) increased and (b) decreased BMI are shown. Three variant collapsing
- models were tested for each gene and the one with the lowest *P* value in the combined metaanalysis is shown here. † indicates known BMI genes. Data for all genes contributing to change
- in BMI (including those contributing to $>1 \text{ kg/m}^2$) are provided in **Supplementary Table 4**.

Genes		Beta (95% CI)	<i>P</i> value
GPR75		-0.84 (-2.00, 0.32) -1.47 (-1.69, -1.25) -1.11 (-1.81, -0.42)	1.57x10 ⁻⁰¹ 0 1.64x10 ⁻⁰³
GIPR	•	-1.12 (-1.54, -0.70) -0.44 (-0.92, 0.05) -0.92 (-1.34, -0.51)	1.65x10 ⁻⁰⁷ 8.02x10 ⁻⁰² 1.29x10 ⁻⁰⁵
DPP9		-0.67 (-2.38, 1.03) -1.29 (-2.53, -0.06) -0.82 (-1.94, 0.31)	4.40x10 ⁻⁰¹ 4.06x10 ⁻⁰² 1.55x10 ⁻⁰¹
GPR151		-0.27 (-0.77, 0.23) -0.11 (-0.33, 0.12) -0.24 (-0.57, 0.09)	2.85x10 ⁻⁰¹ 3.60x10 ⁻⁰¹ 1.51x10 ⁻⁰¹
ZFHX3		0.07 (-0.66, 0.81) 0.81 (-0.46, 2.08) 0.23 (-0.39, 0.86)	8.44x10 ⁻⁰¹ 2.13x10 ⁻⁰¹ 4.59x10 ⁻⁰¹
ANKRD27		0.71 (0.63, 0.79) -0.05 (-0.07, -0.03) 0.33 (-0.05, 0.71)	0 1.78x10 ⁻⁰⁷ 8.47x10 ⁻⁰²
RAPGEF3	•	0.65 (0.04, 1.26) 0.09 (-0.33, 0.51) 0.41 (-0.04, 0.85)	3.62x10 ⁻⁰² 6.62x10 ⁻⁰¹ 7.32x10 ⁻⁰²
ATP13A1		0.76 (0.27, 1.25) 0.40 (0.32, 0.48) 0.64 (0.31, 0.97)	2.28x10 ⁻⁰³ 0 1.42x10 ⁻⁰⁴
KSR2		1.25 (-3.47, 5.98) 0.80 (-1.75, 3.34) 1.08 (-1.69, 3.86)	6.03x10 ⁻⁰¹ 5.41x10 ⁻⁰¹ 4.44x10 ⁻⁰¹
SPARC		0.92 (-0.47, 2.30) 1.68 (1.28, 2.09) 1.24 (0.39, 2.08)	1.95x10 ⁻⁰¹ 2.22x10 ⁻¹⁶ 4.19x10 ⁻⁰³
PTPRG		1.50 (0.53, 2.48) 1.05 (-0.06, 2.16) 1.27 (0.61, 1.93)	2.39x10 ⁻⁰³ 6.33x10 ⁻⁰² 1.61x10 ⁻⁰⁴
RAB21		2.22 (-4.92, 9.35) 1.44 (1.31, 1.56) 1.75 (-1.46, 4.96)	5.43x10 ⁻⁰¹ 0 2.86x10 ⁻⁰¹
ANO4		2.34 (0.21, 4.47) 1.44 (0.70, 2.18) 1.87 (0.71, 3.04)	3.10x10 ⁻⁰² 1.44x10 ⁻⁰⁴ 1.64x10 ⁻⁰³
TOX4		2.06 (-0.16, 4.29) 3.89 (0.08, 7.71) 2.85 (0.91, 4.79)	6.93x10 ⁻⁰² 4.56x10 ⁻⁰² 4.02x10 ⁻⁰³
DIDO1		3.22 (-1.14, 7.58) 2.82 (2.04, 3.61) 3.03 (0.80, 5.25)	1.47x10 ⁻⁰¹ 1.59x10 ⁻¹² 7.70x10 ⁻⁰³
– 5	0 5 10 Effect Size		lon-European meta uropean meta Combined meta

136

137 Supplementary Fig. 1: Effect of previously identified BMI-associated genes across

ancestries. Effect sizes along with 95% confidence intervals (CI) and significance values (P 138

139 value) in European, non-European, and combined meta-analysis for genes previously associated

140 with BMI are shown. Three variant collapsing models were tested for each gene and the one with

- 141 the lowest P value in the combined meta-analysis is shown here. Extended data are available in
- 142 143 Supplementary Table 5.
- 144
- 145



146 147

148 Fig. 2: Interpopulation variance of known and discovered BMI genes. Interpopulation

149 variance plot with effect sizes along x-axis and variance of effect sizes across populations along 150 y-axis of previously identified (in red diamond) and discovered (in purple dots) BMI genes are

151 shown. Three variant collapsing models were tested for each gene and the one with the lowest P

152 value in the combined meta-analysis is shown here. Extended data are available in

- 153 **Supplementary Table 6**.
- 154
- 155

156 Cardiometabolic profile of carriers of PTVs in BMI-associated genes

- 157 We next examined whether PTV carriers in the BMI-associated genes were enriched across
- 158 different obesity categories, namely, underweight/normal (BMI<25), overweight (25≤BMI<30),
- 159 obese (30≤BMI<40), and severely obese (BMI≥40). Of the BMI-increasing genes, PTV carriers
- 160 in 35 genes, including NCOR1 (OR=1.28, 95% CI: 1.04, 1.58, P=0.02), SEC24B (OR=1.46,
- 161 95% CI: 1.04, 2.04, P=0.02), ADNP (OR=1.77, 95% CI: 1.15, 2.7, P=0.007), and ANGPT2
- 162 (OR=1.62, 95% CI: 1.08, 2.42, P=0.01), showed higher odds for obesity, while PTV carriers in
- 163 22 genes, including MACROD1 (OR=2.11, 95% CI: 1.31, 3.25, P=0.002), ICE1 (OR=1.74, 95%
- 164 CI: 1.06, 2.73, *P*=0.01), and *MYOG* (OR=7.47, 95% CI: 1.73, 25.21, *P*=0.004), showed higher
- 165 odds for severe obesity (Fig. 3a, Supplementary Fig. 2, Supplementary Table 7). Of the BMI-

166 decreasing genes, PTV carriers in 15 genes, including NEUROD6 (OR=2.78, 95% CI: 1.05, 7.61, 167 P=0.03), DCUN1D3 (OR=2.49, 95% CI: 1.00, 6.22, P=0.04), SH3GL2 (OR=2.4, 95% CI: 1.49, 168 3.87, P=0.0001), and VIRMA (OR=1.47, 95% CI: 1.11, 1.94, P=0.006), were more likely to be 169 underweight or normal than individuals without PTVs in those genes (Fig. 3a, Supplementary 170 Fig. 2, Supplementary Table 7). Further, individuals with PTVs in VIRMA (OR=0.51, 95% CI: 171 0.35, 0.73, P=7.18x10⁻⁵), RABEP1 (OR=0.53, 95% CI: 0.32, 0.85, P=0.005), CDK7 (OR=0.67, 172 95% CI: 0.46, 0.96, P=0.03), and P2RY1 (OR=0.44, 95% CI: 0.18, 0.96, P=0.03) were less likely 173 to be obese, while individuals with PTVs in AQP3 (OR=0.13, 95% CI: 0.003, 0.76, P=0.01) and 174 TSPAN4 (OR=0.46, 95% CI: 0.22, 0.86, P=0.01) were also less likely to be severely obese. This 175 analysis confirmed obesity risk and protective effects of the BMI-associated genes discovered in 176 our study.

We also found significantly altered risks for 15 obesity-related comorbidities in carriers of PTVs in both obesity-risk conferring and protective genes compared to non-carriers (**Fig. 3b**,

179 **Supplementary Table 8**). For instance, individuals with PTVs in LPGAT1 showed higher risks

180 for 5 out of 15 comorbidities, including aortic valve stenosis (OR=4.05, 95% CI: 1.46, 9.07,

181 *P*=0.005), heart failure (OR=2.33, 95% CI: 1.17, 4.21, *P*=0.01), and knee osteoarthritis

182 (OR=2.27, 95% CI: 1.40, 3.55, *P*=0.0006). Notably, *TMEM229A*, despite conferring obesity

183 risk, showed depletion for heart failure phenotype in carriers (OR=0, 95% CI: 0, 0.93, P=0.03).

184 Among the obesity protective genes, PTV carriers in *VIRMA* and *SCFD1* showed reduced risk

185 for most of the tested cardiometabolic phenotypes, including significant depletion for venous

186 thromboembolism (OR=0, 95% CI: 0, 0.65, *P*=0.008) and hypertension (OR=0.49, 95% CI:

187 0.28, 0.85, *P*=0.007), respectively. Further, PTV carriers in the BMI-decreasing *PANK1* and

188 *P2RY1* exhibited an increased risk for type 2 diabetes (OR=1.74, 95% CI: 1.16, 2.54, *P*=0.005)

and heart failure (OR=2.82, 95% CI: 0.87, 7.11, P=0.04), respectively. While obesity risk-

190 conferring genes typically associated with worse cardiometabolic profiles and protective genes

191 with better profiles, notable exceptions were observed where obesity protective genes conferred

192 risk and risk genes were protective for certain cardiometabolic phenotypes.





195 Fig. 3: Enrichment of obesity and cardiometabolic comorbidities in PTV carriers of the

196 **discovered BMI associated genes**. (a) *Top*: Proportion of PTV carriers within the obesity

197 clinical categories (underweight or normal, overweight, obese, and severely obese) that led to at

198 least 1.5 kg/m² increase (risk) or decrease (protective) in BMI. *Bottom*: Odds ratio of obesity

199 clinical categories in carriers compared to non-carriers. *P<0.05. Extended data with the odds

- ratios, 95% confidence intervals and exact *P* values are available in **Supplementary Table 7. (b)**
- 201 Odds ratio for obesity-related comorbidities in PTV carriers of risk or protective genes compared
- to non-carriers. *P < 0.05, **P < 0.01, ***P < 0.001. Extended data with the odds ratios, 95%
- 203 confidence intervals and exact *P* values are available in **Supplementary Table 8**.
- 204



205

Supplementary Fig. 2: Enrichment in obesity clinical categories for BMI-associated genes. Proportion of PTV carriers in obesity clinical categories that led to between 1 to 1.5 kg/m^2 increase (risk) or decrease (protective) in BMI. The odds ratio of being underweight or normal, overweight, obese, and severely obese among carriers compared to non-carriers is also shown in the table below (**P*<0.05). All data with the odds ratio, 95% confidence intervals, and exact *P* values are available in **Supplementary Table 7**.

212

213 Functional analysis of obesity-associated genes

214 We evaluated the impact of natural variation in plasma protein levels of the discovered genes on

215 BMI of individuals from the UK Biobank, irrespective of their PTV carrier status. Among the

216 discovered BMI-associated genes, six had plasma protein measurements from approximately

217 50,000 individuals. We constructed linear models using protein expression as the independent

218 variable and BMI, corrected for covariates, as the dependent variable. All six proteins had

significant model coefficients, with DNER having the highest absolute effect on BMI (Fig. 4a,

220 Supplementary Table 9), consistent with the association of *DNER* PTVs with severe obesity.

221 Protein levels of FGF2 (β =0.21, P=3.87 x 10⁻¹⁴) and GLOD4 (β =0.79, P=7.02 x 10⁻⁵³)

associated with increased BMI, supporting the observation that disruption of these genes leads to

a decrease in BMI (Supplementary Fig. 3). Interestingly, increased CD27 and ROBO1 levels

associated with increased BMI, contrary to the expected effect from PTVs in these genes, which

- resulted in increased BMI. This suggests a complex relationship between protein expression of
- these genes and their effect on BMI. Our results show that natural variation in protein expression
- 227 levels, potentially due to other common or rare non-coding variants, of the genes identified in
- 228 our study are associated with BMI.

229 We next assessed whether the 116 novel genes identified in our study had been 230 previously linked to obesity or related pathways using genetic and functional approaches beyond 231 rare variant association studies. Nineteen genes, including MACROD1, VIRMA, and RABEP1, had common variant signals associated with BMI recorded in the GWAS catalog¹⁹ 232 233 (Supplementary Table 10 and 11). We also queried the Common Metabolic Diseases 234 Knowledge Portal²⁰, which aggregates and scores genotype-phenotype relationships (Human 235 Genetic Evidence, or HuGE scores²¹) based on evidence from both rare and common variant 236 association studies. This analysis identified 16 more genes, including LAMB2, FARP2, CELSR3, 237 and ANGPT2, that showed strong associations (HuGE score ≥ 10) with BMI or related phenotypes 238 such as waist-hip ratio adjusted BMI or fasting insulin-adjusted BMI (see Supplementary Table

239 **10 and 11**).

240 We further investigated the functional effects of knocking out obesity-associated genes using data from the International Mouse Phenotyping Consortium²² and previous studies in 241 mouse models. We found that 15 of our novel genes (five associated with risk and ten protective 242 243 against obesity) exhibited directionally consistent obesity-related phenotypes in mice, such as 244 changes in total body fat, lean mass, and glucose tolerance (Table 2). Among the obesity risk-245 conferring genes, we found impaired glucose tolerance, and increased weight gain in mouse models of Lonrf2²², Ncor1²³, and Gabra5²⁴, respectively. Mouse studies further highlighted the 246 247 involvement of these genes in obesity-related processes such as thermogenesis ($Fgf2^{25}$ and Gabra 5^{24}), adipogenesis (*Ncor1*²³), glucose metabolism (*Abca1*²⁶), fatty acid metabolism 248 (Pml^{27}) , and skeletal muscle metabolism $(Mipep^{28})$. We also found direct evidence of protective 249 250 effects from homozygous knockouts of Aqp3, Kctd7, and Fgf2 in mice, resulting in increased 251 lean mass, reduced total body fat, and resistance to obesity with a high-fat diet, respectively 252 (Table 2). In addition, *Dcun1d3* homozygous knockout mice showed a significant reduction in 253 total body fat, increased lean mass, and improved glucose tolerance. Finally, we performed a 254 systematic literature review and found evidence for 71 genes with functional roles in obesity, 255 including MMP3, SLC25A1, CYP3A5, APMAP, and UCP3 (Fig. 4b, Supplementary Table 12). 256 Overall, we found evidence linking 82 out of the 116 discovered genes to obesity or related 257 phenotypes, based on previous association studies, plasma proteomics, and mouse models (Fig. 258 4b, Supplementary Table 11).

259

Risk gene	Evidence from mouse models			
ABCA1	Increased weight gain in adipocyte specific <i>Abca1^{-ad/-ad}</i> KO mouse when a high fat diet ²⁶			
GABRA5	Increased weight gain in chemogenetically inhibited (by clozapine N-oxid mouse when fed a high fat diet ²⁴			
NCOR1	Increased weight gain in adipocyte specific $NCoR^{fl/fl}aP2-Cre^{+/-}$ KO mous when fed a high fat diet ²³			
LONRF2	Impaired glucose tolerance observed in <i>Lonrf2^{em2(IMPC)H}</i> homozygous KO mouse model			
ANGPT2	Protection from high fat diet induced obesity in adipose tissue specific overexpressed (by doxycycline) mouse ²⁹			
Protective gene	Evidence from mouse models			
DCUNID3	Decreased total body fat mass, increased lean body mass and improved glucose tolerance observed in <i>Dcun1d3em1(IMPC)Wtsi</i> homozygous KO mou			
AQP3	Increased lean body mass observed in <i>Aqp3^{tm2b(EUCOMM)Wtsi}</i> homozygous F			
SNAP29	Increased lean body mass observed in <i>Snap29^{tm1a(EUCOMM)Wtsi}</i> heterozygou KO mouse			
KCTD7	Decreased total body fat amount observed in <i>Kctd7^{em2(IMPC)Bay}</i> homozygov KO mouse model			
FGF2	Protection from high fat diet induced obesity in $Fgf2^{-/-}$ homozygous KO mouse ²⁵			
MTFP1	Protection from high fat diet induced obesity in liver specific <i>Alb</i> - $Cre^{ig/+}Mtfn l^{LoxP/LoxP}$ KO mouse ³⁰			
SETX	Improved glucose tolerance observed in <i>Setx</i> ^{<i>tm1b</i>(<i>EUCOMM</i>)<i>Wtsi</i> homozygous KO mouse}			
MIPEP	Protection from high fat diet induced obesity in adipocyte specific $miPEP^{flox/flox}Adiponectin-Cre^{+/-}$ KO mouse ²⁸			
AHNAK	Improved glucose tolerance observed in <i>Ahnak</i> ^{tm1b(KOMP)Mbp} heterozygous KO mouse			
PML	Protection from western diet induced obesity in $Pml^{-/-}$ mouse ²⁷			





265 Fig. 4: Functional validation of BMI associated genes. (a) Model coefficients, with 95 % CI 266 and P value, of a linear model constructed using plasma protein expression values of BMI-267 associated genes as independent variable and BMI as the dependent variable. Data with exact P values, model coefficients and 95% confidence interval are available in Supplementary Table 268 269 9. (b) Upset plot of evidence for a role of the identified BMI-associated genes in obesity-related 270 functions and phenotypes. The bars represent the number of genes with functional relevance 271 found from the respective study, which is represented by the dots. RVAS, Rare variant 272 association study; IMPC, International mouse phenotypic consortium; GWAS: Genome wide 273 association study; CMDKP: Common metabolic diseases knowledge portal. 274





276 277

Supplementary Fig. 3: Relationship between plasma protein levels and BMI. Association of
the plasma protein levels with BMI in the population (grey scatters) and the PTV carriers (red
scatters) for (a) DNER, (b) FGF2, (c) GLOD4, (d) CD27, (e) ROBO1, (f) MMP3.

281 Interactions of obesity-associated genes with polygenic risk and lifestyle factors

282 We assessed how PGS modulated the effect of the identified genes on BMI (Supplementary 283 Fig. 4a). We used linear regression to test multiplicative interactions between PGS and each 284 disrupted gene towards changes in BMI. We identified four scenarios where PGS contributed to 285 the variability in BMI among individuals with PTVs in the same gene (Fig. 5a and b, 286 **Supplementary Fig. 4b**). In the *first* scenario, BMI was synergistically increased by both PGS 287 and PTVs in risk genes, leading to more severe obesity. For example, individuals with PTVs in 288 TSFM, LPGAT1, FAM171A2, ICE1, TNK2, and TPRX1 and eight other genes showed a 289 synergistic increase in BMI in concert with PGS. This pattern was more evident in carriers of 290 BSN PTVs where a non-additive increase in BMI was observed across PGS quintiles (Fig. 5c). 291 Second, the combined effect of PGS and PTVs in five risk genes, including UBR2 and PAM, was 292 much lower than their expected additive effects on BMI (Fig. 5c). Third, PGS was found to 293 override the effect of six protective genes such as SH3GL2 and APMAP, and individuals with 294 high PGS still showed increased BMI despite carrying PTVs in BMI-decreasing genes (Fig. 5c). 295 In the *fourth* scenario, we noted that 23 protective genes override the strong obesity risk-296 conferring effect of PGS, and individuals remain protected despite carrying high polygenic risk 297 for obesity. For example, the effect of PGS in the highest quintile among carriers of PTVs in 298 *VIRMA* was 2.53 kg/m² less than in non-carriers (Fig. 5c). We did not identify non-additive 299 effects of PGS on other disrupted genes such as MC4R, APBA1 and ROBO1, consistent with 300 previous reports^{7,9} (Supplementary Table 13).

301 We next investigated the effect of obesity-inducing lifestyle factors on the BMI of PTV 302 carriers after controlling for PGS. We found that the effects of PTVs in MACROD1 and VIRMA 303 was modulated by the degree of physical activity of individuals. In particular, individuals 304 carrying MACROD1 PTVs with low physical activity (UKB) or bad physical health (AoU) had a 305 higher BMI compared to non-carriers, in both UKB and AoU cohorts (Fig. 5d, Supplementary 306 Table 14). On the other hand, the protective effect of VIRMA was more pronounced in 307 individuals with low physical activity in the UKB cohort but was diminished in individuals self-308 reported to be in bad physical health in the AoU cohort (Supplementary Fig. 4c, 309 Supplementary Table 14). This observation could be attributed to differences in how lifestyle 310 factors are measured across UKB and AoU, or other cohort-specific factors. We also identified 311 associations for carriers of MC4R, TNK2, and GADL1 PTVs with diet, sleep, and sedentary

- 312 lifestyle factors, respectively, in UKB (Supplementary Table 15), but these associations could
- 313 not be tested in AoU due to the lack of comparable data. Our results underscore the influence of
- 314 PGS and obesogenic factors towards the effect conferred by obesity risk and protective genes.
- 315





- and PGS on BMI, categorized by the four different scenarios. Data with exact *P* values and other
- 320 associated statistics are available in **Supplementary Table 13. (b)** Interaction plots showing the
- 321 mean BMI of PTV carriers and non-carriers in the higher (fourth and fifth) and lower (first,
- 322 second, and third) PGS quintiles are shown. The PTV carriers of genes were aggregated based on
- their interaction category with PGS. (c) BMI distribution across PGS quintiles of PTV carriers
- 324 (blue) compared to non-carriers (grey) of the representative examples for each of the four

325 interaction scenarios. (d) BMI distribution of MACROD1 PTV carriers compared to non-carriers,

326 stratified by their physical activity levels in UKB (left) and AoU (right) cohorts.





- 329 Supplementary Fig. 4: Effect of obesity-associated genes modulated by polygenic and
- **330 obesogenic risk factors**. (a) BMI distribution of PTV carriers in high-effect obesity genes. (b)
- 331 Interaction plots depicting the different scenarios through which PGS modulates the BMI of

individuals with PTVs in the discovered genes. (c) BMI distribution of carriers of PTVs in

333 *VIRMA* compared to non-carriers stratified by their physical activity levels in UKB (left) and

- AoU (right) cohorts.
- 335

336 **DISCUSSION**

Here, we discovered 116 genes with consistent effects on BMI across ancestries and provide 337 338 accurate estimates of effect sizes for known obesity genes. By using genetic data from both 339 European and non-European populations, we uncovered gene-discovery biases present in 340 previous studies particularly in genes such as DIDO1, SPARC, and RAB21 that showed 341 significant associations only in Europeans. Typically, protective obesity genes have been more 342 challenging to identify than risk genes, but three notable ones, GPR75, GPR151, and GIPR, have emerged more recently through rare variant association studies^{6,9,31}. However, our findings 343 344 suggest that these genes may also be influenced by ancestral biases, with variable effect sizes 345 across populations, which could impact their potential as therapeutic targets for obesity. In 346 contrast to previous studies, we identified genes with consistent effects across ancestries and 347 functional evidence, such as mouse knockout models for these genes, confirm their role in 348 obesity-related pathways. These findings emphasize the value of a cross-ancestry analysis, which 349 enabled the discovery of several novel genes with effect sizes comparable to canonical obesity 350 genes such as MC4R and BSN.

351 A significant finding from our study was the identification of 66 protective genes, some 352 of which exhibit effect sizes more than twice that of known protective genes. Notably, 353 DCUNID3 showed the highest effect size, with PTVs in these genes leading to approximately 354 3.8 kg/m² decrease in BMI. This gene is highly expressed in adipocytes, and *Dcun1d3* knockout 355 mice showed reduced fat body mass, increased lean body mass and improved glucose 356 tolerance²². DCUN1D3 encodes a protein involved in neddylation, a post translation 357 modification that attaches a small ubiquitin-like molecule, NEDD8, to substrate proteins, altering 358 their properties^{32,33}. Disruption of neddylation has been linked to impaired energy metabolism 359 and age-related metabolic disorders^{34,35}. While the mechanisms by which *DCUNID3* might 360 influence these pathways or diseases are unclear, our findings suggest that its inhibition could be 361 a therapeutic target for obesity. Similarly, VIRMA consistently led to decreased BMI, is supported by evidence from nearby common variant signals¹⁹, and individuals with PTVs in this 362 363 gene displayed improved cardiometabolic health. Two other protective genes, AQP3 and FGF2,

364 not only showed evidence from mouse models for obesity protection but also have wellestablished functional roles in glycerol metabolism³⁶ and thermogenesis²⁵. Currently, 365 366 pharmacological inhibitors or negative modulators, such as Bisacodyl and Pentosan polysulfate, 367 exist for AOP3 and FGF2; however, they are used as a laxative and for bladder pain, 368 respectively³⁷. We also found that Setmelanotide, the MC4R agonist used for weight loss, is also 369 an agonist of ANGPT2, an obesity risk gene discovered in our study, with evidence from mouse models demonstrating its role in body weight regulation^{29,38}. Thus, our discoveries provide 370 371 avenues for repurposing existing drugs or devising new ones to alleviate obesity risk. 372 While polygenic risks have been found to additively influence rare variant risk for 373 obesity⁹, a recent study showed BSN and PGS interact non-additively. In addition to 374 recapitulating the effect between BSN and PGS, we found synergistic effects of PGS on other genes, such as TSFM, LPGAT1, and FAM171A2, as well. Further, synergistic interactions 375 376 between obesity causing risk factors can also exacerbate the risk of severe obesity and its 377 associated morbidities. For instance, carriers of PTVs in MACROD1, an obesity risk gene, 378 showed significantly higher BMI when they were physically inactive compared to carriers who 379 were active. While previous studies have shown the adverse effect of lifestyle factors on 380 common variants associated with BMI², we provide evidence that rare variant risk can be 381 modulated by obesogenic factors. Notably, carriers of PTVs in protective genes such as VIRMA 382 and PI4KB, remained protected despite having high PGS, highlighting the complex patterns of 383 interactions between specific obesity genes and PGS. Understanding these genetic and gene-384 environment interactions could be key to developing more effective interventions, where lifestyle 385 changes may mitigate genetic risk in high-risk individuals, and protective variants might offer 386 resilience against obesogenic factors. Overall, using a multi-ancestry approach, we provide a 387 more comprehensive view of obesity genetics, identifying novel genes, refining the effects of 388 known genes, and demonstrating the importance of including diverse populations in genetic 389 studies.

390

391 METHODS

392 Variant quality control, filtering, and annotation

393 We analyzed whole exome sequencing data of 469,835 individuals from the UK Biobank (UKB) 394 cohort, available as multi-sample project variant call format (pVCF) files in the UKB Research 395 Analysis Platform (RAP). The sequencing method and preparation of the pVCF files have been 396 previously described³⁹. Using the Hail⁴⁰ platform on DNANexus, we first split multi-allelic 397 records, and then filtered to retain rare variants with intracohort frequency <0.001. These 398 variants were annotated using variant effect predictor⁴¹ (VEP v109) and dbNSFP v4⁴² to identify 399 the predicted variant effects on gene transcripts. All variants within protein coding genes in the 400 autosomes with a call rate of 50% were used for subsequent analysis. We then annotated each 401 variant based on their most deleterious functional impact on the transcript into three categories, 402 from the most harmful to the least harmful, as follows: (1) Loss of function or "lof", which 403 included frameshift, stop gained, splice acceptor, and splice donor VEP annotations, (2) 404 "missense strict", which included missense variants predicted to be deleterious by nine deleteriousness prediction tools (SIFT⁴³, LRT⁴⁴, FATHMM⁴⁵, PROVEAN⁴⁶, MetaSVM⁴⁷, 405 406 MetaLR⁴⁷, PrimateAI⁴⁸, DEOGEN2⁴⁹, and MutationAssessor⁵⁰) available through dbNSFP 407 database, and (3) "missense lenient", which included missense variants predicted to be 408 deleterious by at least seven out of the nine deleteriousness prediction tools. All UKB analyses 409 were performed in the DNANexus UKB RAP.

We also analyzed whole genome sequencing data of 245,388 individuals in the All of Us (AoU) cohort. Variant call files for regions overlapping with the exomes were available as a Hail matrix table in the AoU portal. After filtering the variants for intracohort frequency (<0.001), we annotated the variants using Nirvana⁵¹, available in the AoU research platform as a Hail table, and determined the functional impact of each variant using the same criteria as defined for the UKB data. All AoU analyses were performed in the Researcher Workbench of the AoU portal.

417 Phenotype, obesogenic lifestyle, polygenic risk analyses

418 For the UKB cohort, BMI, genetic sex (Data Field 22001), age (Data Field 21003), ethnic

419 background (Data Field 21000), PGS (Data Field 26216), genetic kinship (Data Field 22021),

420 and the top 40 genetic principal components (PCs; Data Field 22009) on 502,368 individuals in

421 UKB were accessed and preprocessed through the UKB RAP. Numerical fields such as BMI and

422 age, measured across multiple visits, were averaged. Categorical fields such as sex and ethnic 423 background were searched for inconsistent readings, and samples with conflicting values across 424 multiple assessments were dropped. We further filtered samples with 10 or more third-degree 425 relatives from our analysis based on previously published kinship estimates¹⁴. We finally divided 426 the cohort into two populations, based on their ethnic background namely, "British" consisting of 427 419,228 individuals self-reported to be "White British" based on the UKB data-field 21000, and 428 the other 68,070 individuals who we categorized as "non-British" population. We note that the 429 UKB non-British population contains individuals of European ancestry, for example, individuals 430 with self-reported "Irish" ethnic background. **Obesogenic lifestyle factors** such as Metabolic 431 Equivalent Task (MET) scores, sleep duration, alcohol consumption, or smoking habits were 432 also accessed and preprocessed through the UKB RAP. Numerical fields were averaged and 433 samples with categorical fields having conflicting values across multiple assessments were 434 dropped. All fields were then binarized based on their extreme values and their potential effect 435 on BMI as follows: Numerical fields with the potential to have a directly proportional effect on 436 BMI, such as "time spent watching television", were assigned as 1 for an individual, if their 437 corresponding value was greater than 95% quantile. On the other hand, fields with inversely 438 proportional effect on BMI, such as "consumption of cooked vegetable", were assigned as 1 if 439 the value was less than 5% quantile. Individuals with extreme values from ordinal fields that 440 potentially lead to increased BMI were assigned as 1, and individuals with all other values were 441 assigned as 0. For example, individuals who consumed alcohol daily or almost daily, the extreme 442 category for this field, were encoded as 1 for that lifestyle factor. A full description of the 443 lifestyle factors used in this study and the thresholds or categories used to binarize them is 444 available in **Supplementary Table 16**. After binarizing, the fields were combined to define one 445 of the six lifestyle factors, namely, (i) physical activity, (ii) alcohol, (iii) smoke, (iv) diet, (v) 446 sleep, and (vi) sedentary lifestyle, used in this study. Binarized MET scores, alcohol 447 consumption frequency, and sleep patterns were directly used as indicators of physical activity, 448 alcohol, and sleep metrics, respectively. Individuals whose current or past smoking tendencies 449 were high were considered to have the "smoke" lifestyle. Similarly, those spending more time on 450 TV or computer were indicative of "sedentary lifestyle". Diet was denoted as 1 if either the sum 451 of high processed meat-, beef-, mutton-, and pork-intake binarized columns was greater than 0, 452 or the sum of low cooked vegetable, salad, fresh fruit, dried fruit, oily fish, or non-oily fish-

intake binarized columns was greater than 1. Thus, the diet field used in the study is analogous to
high-meat and/or low vegetable consumption. International Classification of Disease (ICD-10)
10th revision summary diagnosis codes corresponding to each individual were also extracted
from the Hospital Episode Statistics (HES) data available in the UKB RAP.

457 For the AoU cohort, we obtained BMI, age, genetic sex, previously calculated genetic 458 ancestry¹⁵, 16 genetic PCs, and sample IDs of related individuals from the AoU Workbench. We 459 calculated the age based on the date of birth and the BMI measurement data concepts ("concept" 460 defined here as a collection of similar data stored together) available in AoU. We used the "sex 461 at birth" concept, available in AoU, to denote the genetic sex of an individual. Only individuals with BMI values between 12 and 75 kg/m² and "sex at birth" field listed as either "Male" or 462 463 "Female" were included to ensure consistency between UKB and AoU. Based on the predicted 464 genetic ancestry, we divided the AoU data into three populations namely, (1) European 465 (N=127,644), which included individuals predicted to be of European ancestry, (2) African 466 (N=54,865), which included individuals predicted to be of African ancestry, and (3) Mixed 467 (N=52,134), which included individuals predicted to be of Admixed American ancestry and 468 other ancestries. We calculated PGS for BMI in individuals from AoU by using the GWAS 469 summary statistics from a previous study⁴. Duplicate and ambiguous single nucleotide 470 polymorphism (SNPs) were filtered from the summary statistics. Genotype data of the AoU 471 cohort filtered for common variants (MAF>0.01) was obtained as a Hail matrix table. We further removed variants with Hardy-Weinberg Equilibrium p-value $<1x10^{-6}$ and retained variants that 472 473 overlapped between summary statistics data and the AoU genotyped data with a call rate greater 474 than 0.9. We then used the predetermined effect sizes of the SNPs as Bayesian priors, weighed 475 them based on the alternate allele frequency observed in individuals, and summed the weighted 476 effect sizes to obtain individual-specific polygenic risk for BMI. All calculations were conducted 477 using Hail, available in the AoU Researcher Workbench. *Obesogenic lifestyle factors* such as 478 physical activity, alcohol consumption, and smoking tendency in the AoU cohort were obtained 479 from survey questionnaires available through the AoU research portal. Individuals falling in the 480 extreme categories for each of the three factors, (1) Physical activity: "General Physical Health: 481 Fair" or "General Physical Health: Poor", (2) Alcohol consumption, "Drink Frequency Past 482 Year: 4 or More Per Week", and (3) Smoking tendency: "Smoke Frequency: Every Day", were 483 annotated as 1, denoting those carrying the respective obesogenic factor, while others not falling

in these extreme categories were annotated as 0. We note that physical activity measurements in
AoU were not equivalent to those in UKB, where a more rigorous assessment of an individual's
physical health was measured using International Physical Activity Questionnaire guidelines.
Additionally, diet and sedentary lifestyle information was not available in AoU, while sleep data
were available on less than 10% of the cohort and these lifestyle factors could not be tested in
AoU. ICD-10 diagnosis codes corresponding to each individual in the AoU cohort was extracted
using the researcher workbench.

491

492 Gene burden association test using REGENIE

493 We used REGENIE $v3.3^{16}$ to conduct gene burden association tests. Similar to most whole 494 genome regression tools, REGENIE operates in two steps. First, it uses SNP data, preferably a 495 genotyped array of SNPs, from across the genome to fit a null model that estimates a polygenic 496 score for the trait to be tested (i.e., BMI in our study). This step accounts for population structure 497 and relatedness between samples. For both UKB and AoU cohorts, we used the genotyped SNP 498 array files available in DNANexus or Researcher workbench for this step. We lifted over the 499 SNP array files in UKB from version hg19 to hg38 using Picard's LiftoverVCF tool⁵². In the 500 second step, REGENIE then calculates the association between the genetic variants of interest 501 and the trait after considering the null model calculated in step 1 and other user defined 502 covariates. In our study, we used age, genetic sex, and first ten genetic PCs obtained from both 503 UKB and AoU cohorts as additional covariates. REGENIE is capable of collapsing variants to a 504 gene-level with user defined masks and annotation files apart from the usual variant data as input 505 before running association tests. We supplied our already annotated variant file based on their 506 impact on gene transcripts and defined three variant masks to collapse variants on a gene level, 507 namely, (a) "lof" variants only, (b) "lof" and "missense strict" variants, and (c) "lof", "missense 508 strict" and "missense lenient" variants. We performed gene-based association tests for all the five 509 defined populations across both biobanks and generated statistics for all individual gene-mask 510 pairs.

511

512 Meta analysis and variance calculation

513 We first created three meta populations from the previously defined five populations (UKB

514 British, UKB non-British, AoU European, AoU African, and AoU Mixed), the first composed of

515 individuals from European ancestry (UKB British and AoU European) termed "European meta",

516 the second from non-European ancestry (UKB non-British, AoU African and AoU Mixed)

termed "non-European meta", and the third from all five populations termed "combined meta".

518 We note that a minority of individuals (approximately 15%) in the non-European population

519 were from ethnic groups such as 'Irish' or 'any other white background', and are therefore likely

520 to be of European ancestry.

521 Results from the individual populations were pooled into the three meta populations 522 using an inverse variance weighted random effects model. The meta-analysis calculation was 523 implemented using the python package statsmodels v0.14.2. Each gene-variant mask was 524 associated with meta statistics for three meta populations. Any gene-variant mask that passed the 525 Bonferroni multiple testing correction threshold of 8.34x10⁻⁷, accounting for 20,000 genes and 526 three variant collapsing models, *either* in the European meta or the non-European meta and in 527 the combined meta population were considered to be significantly associated with BMI across 528 ancestries.

529 We calculated the interpopulation variance in effect sizes across populations for the 530 discovered genes passing our multiple testing criterion, as well as previously associated BMI 531 genes, using the "var" method available in the python package, pandas v2.1.1.

532

533 Odds-ratio calculation for obesity clinical categories and obesity-related disorders

To calculate risk across the obesity clinical categories among carriers of PTVs in the discovered genes compared to non-carriers, we first categorized each individual into their respective clinical category based on their BMI values: underweight or normal (<25), overweight (25 to 30), obese (30 to 40) and severely obese (>40). We then created 2x2 contingency tables using their carrier status as the first variable and whether they belong to the respective obesity category as opposed to any other category as the second variable. Finally, we calculated the conditional odds ratio and the significance value using a two-sided Fisher's exact test.

541 To calculate risk for obesity related disorders, we obtained the specific ICD codes for 542 comorbidities frequently associated with obesity based on previous BMI related studies and 543 calculated the odds of PTV carriers diagnosed with the comorbidity compared to non-carriers 544 using Fisher's exact test. A list of the comorbidities and the ICD codes used to categorize an

545 individual as carrying the comorbidity is provided in **Supplementary Table 17**. All odds ratio

546 calculations were conducted using the scipy v1.11.3 package available in python.

547

548 Functional analysis of the discovered genes

549 We overlapped the list of discovered genes with a BMI gene list obtained from the GWAS catalogue¹⁹, where the SNPs identified in previous BMI GWAS studies are mapped to their most 550 551 likely gene targets. We further overlapped the discovered gene list with gene phenotype 552 associations from Common Metabolic Diseases Knowledge Portal (CMDKP) database²⁰. 553 CMDKP aggregates information and scores genotype-phenotype relationships (Human Genetic 554 Evidence or HuGE scores²¹) based on the evidence acquired from previous rare and common 555 variant association studies for all common metabolic disorders, including obesity and related 556 phenotypes. Any gene that showed strong associations (HuGE score >10, indicating "strong" 557 evidence of gene-phenotype link) with obesity, BMI, or related phenotypes, such as fasting 558 insulin adjusted BMI, or waist hip ratio adjusted BMI, were considered an overlapping BMI 559 related gene. Associations of the discovered genes with previous in vivo studies of knockout 560 (KO) mouse models were first identified using data from the International Mouse Phenotyping 561 Consortium (IMPC)²², which provides comprehensive phenotypic characterization of mouse 562 KOs, including assessments of body weight and obesity-related traits. IMPC represents an 563 unbiased resource for investigating the in vivo effects of novel genes that have not been studied 564 in the context of obesity. Further, we conducted a PubMed search of each gene by searching for 565 the gene name in the abstract or title and "obesity" in the text. This provided additional 566 functional evidence for the novel genes, which have been phenotypically characterized using 567 mouse models, or other complementary approaches such as human genetic studies. The BMI-568 associated GWAS gene list was directly obtained from NHGRI-EBI catalog, while associations 569 from CMDKP, IMPC, and PubMed were accessed programmatically through their REST API 570 using python's requests v2.31.0 module.

571

572 Proteomics data analysis of oligogenic combinations

573 Normalized plasma protein expression data of 1,463 proteins on 50,956 individuals were

574 accessed through the DNANexus portal of UKB RAP. Multiple replicates of protein readouts

575 were averaged, and protein levels of corresponding genes were identified. Using linear

576 regression models, the effect of protein expression levels for the discovered genes with available

577 protein data on BMI was measured, while accounting for covariates such as age, genetic sex, ten

578 genetic PCs, PGS, and the interaction term between the protein and the PGS. The model was

579 trained using "ols" function from statsmodels v0.14.2 package available in python.

580

581 Interaction models for obesity risk factors

582 To assess interactive effects between each gene and PGS, we used a linear regression model to 583 predict BMI using individual as well as interactive terms between PGS and PTV carrier status 584 for the discovered genes while accounting for age, genetic sex, and ten genetic PCs. We obtained 585 separate model coefficients in UKB and AoU cohorts and then used random effect meta-analysis 586 to combine the statistics from the two cohorts. Interaction terms with meta-analysis P value less 587 than 0.05 were considered significant gene-PGS interactions. The models were trained using 588 "ols" function from statsmodels v0.14.2 package, available in python. 589 To compare interactive effects between lifestyle factors and gene PTV carrier status, we 590 conducted factorial analysis of covariance using the individual gene and lifestyle terms as well as 591 the gene-lifestyle interaction term, while accounting for age, genetic sex, first ten genetic PCs 592 and PGS, separately in UKB and AoU cohorts. Interaction terms that crossed the P value 593 threshold (0.05) in both UKB and AoU were considered significant gene-lifestyle interactions. 594 Model training and calculation of P value significance and confidence intervals were performed 595 using "ols" and "anova lm" function from statsmodels v0.14.2 package available in python.

597 AUTHOR CONTRIBUTIONS

598 S.G and D.B conceived the study, acquired, analyzed and interpreted the data, and wrote the

- 599 manuscript.
- 600

601 ACKNOWLEDGEMENTS

602 We thank Corrine Smolen and Jiawan Sun for critical reading of the manuscript. We thank the

603 participants and investigators in the UK Biobank and All of US research studies who made this

- 604 work possible. This research has been conducted using the UK Biobank Resource under
- Application Number 45023. We also thank the National Institutes of Health's All of Us Research

606 Program for making available the participant data examined in this study. This work was

607 supported by NIH R01-GM121907, resources from the Huck Institutes of the Life Sciences and

608 the Pennsylvania State University to S.G. The authors declare no competing interests.

609

610 Data and code availability

- 611 The UK Biobank and All of Us genetic and phenotypic data analyzed in this study are publicly
- 612 available to registered researchers through their respective analysis portals. Additional
- 613 information about registration for access to the data is available at <u>https://www.ukbiobank.ac.uk/</u>
- 614 and <u>https://www.researchallofus.org/</u> for UK Biobank and All of Us, respectively. The code for
- 615 pre-processing, filtering, annotating genetic data, association tests and statistical analysis is
- 616 available on GitHub (<u>https://github.com/deeprob/BMI_monogenic</u>).

617

619 **REFERENCES**

- 620 1. Kivimäki, M. et al. Body-mass index and risk of obesity-related complex multimorbidity: an
- 621 observational multicohort study. *Lancet Diabetes Endocrinol* **10**, 253–263 (2022).
- 622 2. Kilpeläinen, T. O. et al. Physical activity attenuates the influence of FTO variants on obesity
- 623 risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med* **8**, e1001116 (2011).
- Kim, M. S. *et al.* Association of genetic risk, lifestyle, and their interaction with obesity and
 obesity-related morbidities. *Cell Metab* 36, 1494-1503.e3 (2024).
- 626 4. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology.
- 627 *Nature* **518**, 197–206 (2015).
- 5. Khera, A. V. *et al.* Polygenic Prediction of Weight and Obesity Trajectories from Birth to
 Adulthood. *Cell* 177, 587-596.e9 (2019).
- 630 6. Turcot, V. et al. Protein-altering variants associated with body mass index implicate
- 631 pathways that control energy intake and expenditure in obesity. *Nat Genet* **50**, 26–41 (2018).
- 632 7. Zhao, Y. et al. Protein-truncating variants in BSN are associated with severe adult-onset
- 633 obesity, type 2 diabetes and fatty liver disease. *Nat Genet* **56**, 579–584 (2024).
- 634 8. Zhu, N. et al. Rare predicted loss of function alleles in Bassoon (BSN) are associated with
- 635 obesity. *NPJ Genom Med* **8**, 33 (2023).
- 636 9. Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated with
 637 protection from obesity. *Science* 373, eabf8683 (2021).
- 638 10. Fatumo, S. *et al.* A roadmap to increase diversity in genomic studies. *Nat Med* 28, 243–250
 639 (2022).
- 640 11. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from
- 641 frequent nonsense mutations in PCSK9. *Nat Genet* **37**, 161–165 (2005).

- 642 12. Genovese, G. et al. A risk allele for focal segmental glomerulosclerosis in African
- Americans is located within a region containing APOL1 and MYH9. *Kidney Int* **78**, 698–704
- 644 (2010).
- 13. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
- 646 Studies. *Cell* **177**, 1080 (2019).
- 647 14. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
- 648 *Nature* **562**, 203–209 (2018).
- 649 15. All of Us Research Program Genomics Investigators. Genomic data in the All of Us
- 650 Research Program. *Nature* **627**, 340–346 (2024).
- 651 16. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
 652 binary traits. *Nat Genet* 53, 1097–1103 (2021).
- 17. Paule, R. C. & Mandel, J. Consensus Values and Weighting Factors. *J Res Natl Bur Stand*(1977) 87, 377–385 (1982).
- 18. Kaisinger, L. R. *et al.* Large-scale exome sequence analysis identifies sex- and age-specific
 determinants of obesity. *Cell Genom* 3, 100362 (2023).
- 19. Sollis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource.
- 658 *Nucleic Acids Res* **51**, D977–D985 (2023).
- 659 20. Common Metabolic Diseases Knowledge Portal (cmdkp.org); (RRID:SCR_020937).
- 660 21. Dornbos, P. et al. Evaluating human genetic support for hypothesized metabolic disease
- 661 genes. Cell Metab **34**, 661–666 (2022).
- 662 22. International Mouse Phenotyping Consortium.
- 663 23. Li, P. *et al.* Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances
- 664 PPARγ activity and insulin sensitivity. *Cell* **147**, 815–826 (2011).

- 24. Sa, M. *et al.* Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA. *Nat Metab* 5, 1506–1525 (2023).
- 667 25. Li, H. et al. FGF2 disruption enhances thermogenesis in brown and beige fat to protect
- against adiposity and hepatic steatosis. *Mol Metab* **54**, 101358 (2021).
- 669 26. de Haan, W., Bhattacharjee, A., Ruddle, P., Kang, M. H. & Hayden, M. R. ABCA1 in
- adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. J
- 671 *Lipid Res* **55**, 516–523 (2014).
- 672 27. Cheng, X. et al. Ablation of promyelocytic leukemia protein (PML) re-patterns energy
- balance and protects mice from obesity induced by a Western diet. *J Biol Chem* 288, 29746–
- 67429759 (2013).
- 28. Diaz-Vegas, A. *et al.* Deletion of miPEP in adipocytes protects against obesity and insulin
 resistance by boosting muscle metabolism. *Mol Metab* 86, 101983 (2024).
- 677 29. An, Y. A. et al. Angiopoietin-2 in white adipose tissue improves metabolic homeostasis
- 678 through enhanced angiogenesis. *Elife* **6**, e24071 (2017).
- 679 30. Patitucci, C. *et al.* Mtfp1 ablation enhances mitochondrial respiration and protects against
 680 hepatic steatosis. *Nat Commun* 14, 8474 (2023).
- 31. Jurgens, S. J. *et al.* Rare coding variant analysis for human diseases across biobanks and
 ancestries. *Nat Genet* 56, 1811–1820 (2024).
- 32. Meyer-Schaller, N. *et al.* The human Dcn1-like protein DCNL3 promotes Cul3 neddylation
 at membranes. *Proc Natl Acad Sci U S A* 106, 12365–12370 (2009).
- 685 33. Monda, J. K. et al. Structural conservation of distinctive N-terminal acetylation-dependent
- 686 interactions across a family of mammalian NEDD8 ligation enzymes. *Structure* **21**, 42–53
- 687 (2013).

- 688 34. Yu, M. et al. Emerging role of NEDD8-mediated neddylation in age-related metabolic
- 689 diseases. *Ageing Res Rev* **94**, 102191 (2024).
- 690 35. Zhang, S., Yu, Q., Li, Z., Zhao, Y. & Sun, Y. Protein neddylation and its role in health and
- 691 diseases. *Signal Transduct Target Ther* **9**, 85 (2024).
- 692 36. Madeira, A., Moura, T. F. & Soveral, G. Aquaglyceroporins: implications in adipose biology
- 693 and obesity. *Cell Mol Life Sci* **72**, 759–771 (2015).
- 694 37. Cannon, M. et al. DGIdb 5.0: rebuilding the drug-gene interaction database for precision
- 695 medicine and drug discovery platforms. *Nucleic Acids Res* **52**, D1227–D1235 (2024).
- 696 38. Ni, B. et al. Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and
- 697 metabolic syndrome. *Mol Metab* **65**, 101588 (2022).
- 39. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants. *Nature* 599, 628–634 (2021).
- 700 40. Hail Team. Hail 0.2. (https://github.com/hail-is/hail).
- 41. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).
- 42. Liu, X., Li, C., Mou, C., Dong, Y. & Tu, Y. dbNSFP v4: a comprehensive database of
- transcript-specific functional predictions and annotations for human nonsynonymous and
 splice-site SNVs. *Genome Med* 12, 103 (2020).
- 43. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res* 11,
 863–874 (2001).
- 44. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human genomes. *Genome Res* 19, 1553–1561 (2009).
- 45. Shihab, H. A. et al. Predicting the functional, molecular, and phenotypic consequences of
- amino acid substitutions using hidden Markov models. *Hum Mutat* **34**, 57–65 (2013).

- 46. Choi, Y., Sims, G. E., Murphy, S., Miller, J. R. & Chan, A. P. Predicting the functional effect
- of amino acid substitutions and indels. *PLoS One* 7, e46688 (2012).
- 713 47. Dong, C. et al. Comparison and integration of deleteriousness prediction methods for
- nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet* **24**, 2125–2137
- 715 (2015).
- 716 48. Sundaram, L. et al. Predicting the clinical impact of human mutation with deep neural
- 717 networks. *Nat Genet* **50**, 1161–1170 (2018).
- 49. Raimondi, D. et al. DEOGEN2: prediction and interactive visualization of single amino acid
- variant deleteriousness in human proteins. *Nucleic Acids Res* **45**, W201–W206 (2017).
- 50. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations:
 application to cancer genomics. *Nucleic Acids Res* 39, e118 (2011).
- 722 51. Stromberg, M. et al. Nirvana: Clinical Grade Variant Annotator. in Proceedings of the 8th
- 723 ACM International Conference on Bioinformatics, Computational Biology, and Health
- 724 *Informatics* 596–596 (ACM, Boston Massachusetts USA, 2017).
- 725 doi:10.1145/3107411.3108204.
- 726 52. Picard (http://broadinstitute.github.io/picard/).